Brexpiprazole
Atypical antipsychotic / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Brexpiprazole?
Summarize this article for a 10 year old
Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.[11][13][14] It is an atypical antipsychotic.[11]
Clinical data | |
---|---|
Pronunciation | /brɛkˈspɪprəzoʊl/ brek-SPIP-rə-zohl |
Trade names | Rexulti, Rxulti, others |
Other names | OPC-34712 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615046 |
License data | |
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Atypical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 95% (Tmax = 4 hours)[11] |
Protein binding | >99% |
Metabolism | Liver (mainly mediated by CYP3A4 and CYP2D6) |
Elimination half-life | 91 hours (brexpiprazole), 86 hours (major metabolite) |
Excretion | Feces (46%), urine (25%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.242.305 |
Chemical and physical data | |
Formula | C25H27N3O2S |
Molar mass | 433.57 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects include akathisia (a constant urge to move) and weight gain.[12] The most common side effects among people with agitation associated with dementia due to Alzheimer's disease include headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia).[13]
Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor to aripiprazole (Abilify).[15] It was approved for medical use in the United States in July 2015.[16][17] A generic version was approved in August 2022.[18] Brexpiprazole is the first treatment approved by the US Food and Drug Administration (FDA) for agitation associated with dementia due to Alzheimer's disease.[13]